$10 Billion Deal, page-695

Yes on a scientific level the trial was a "success" because it gave a result (a null one), but by the measure of commercial importance it was a failure. Designing a trial to see a positive difference and then not seeing any difference is what the industry considers a failure.

None of us here have any knowledge of what interest the pharma industry has in BIT225. All we have to work on is the public data (and our experience) and this suggests to me that there is little interest. This is not my opinion alone as it appears to be shared by the entire biotech investor community.